T&L Biotechnology

Product Name

Generic Name

Recombinant Human TGF-β1 Protein

Synonym

CED,DPD1,LAP,TGF-beta1,TGFB,TGFbeta

Product Information

Protein sequence

A DNA sequence encoding the human TGF-β1 (NP_000651.3) was expressed with an Fc tag at the C-terminus.

Expression Host

HEK293 cells

QC Testing Purity

> 90 % as determined by SDS-PAGE

Activity

The ED50, determined by its ability to inhibit the IL-4-dependent proliferation of HT2 mouse T cells, is ≤ 0.5 ng/ml.

Endotoxin Level

< 0.1EU per μg of the protein as determined by the LAL method.

Molecular Mass

The recombinant human TGF-β1 consists of 374 amino acids and predicts a molecular mass of 42.2 KDa.

Formulation

Lyophilized from sterile PBS, pH 7.4. Normally 6% mannitol are added as protectants before lyophilization.

Stability & Storage

24 months at 2℃ to 8℃ in lyophilized state. 

6 months at -20℃ under sterile conditions after reconstitution.

12 months at -80℃ under sterile conditions after reconstitution.

Recommend to aliquot the protein into smaller quantities after reconstituting with water for injection, normal saline or PBS, and keep the diluted concentration above 100μg/mL. Avoid repeated freeze-thaw cycles.

Background

The three mammalian isoforms of TGF-β, TGF-β1, β2, and β3, signal through the same receptor and show similar biological responses. They are multifunctional cytokines that regulate cell proliferation, growth, differentiation and motility, as well as synthesis and deposition of the extracellular matrix. They are involved in various physiological processes, including embryogenesis, tissue remodeling and wound healing. They are secreted predominantly as latent complexes, which are stored at the cell surface and in the extracellular matrix. The release of biologically active TGF-β isoform from a latent complex involves proteolytic processing of the complex and/or induction of proteins conformational changes such as thrombospondin-1. TGF-β1 is the most abundant isoform secreted by almost every cell type. It was originally identified for its ability to induce phenotypic transformation of fibroblasts, and recently it has been implicated in the formation of skin tumors.

References 

1. Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.
2. Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. JExp Ther Oncol. 7(2): 89-97.
3. Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma. Rom J Morphol Embryol. 49(3): 303-8.